Related Experiment Video
Updated: Aug 16, 2025
Destabilization of the Medial Meniscus and Cartilage Scratch Murine Model of Accelerated Osteoarthritis
Published on: July 6, 2022
Teriparatide prevented synovial inflammation and cartilage destruction in mice with DMM
Xu Liang, Sen-Rui Li, Xin-Xin Zhang1
1Department of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Aim:
Emerging data have demonstrated that low-grade inflammation in osteoarthritis, a long-held degenerative disease. The inflamed synovium produces various cytokines that induce cartilage destruction and joint pain. A previous study showed that teriparatide, an FDA approved anti-osteoporotic drug, may enhance cartilage repair. Our study focuses on its role in OA synovitis.
Materials And Methods:
Primary mouse articular chondrocytes were used to determine the most potent cytokines involved in OA inflammation and cartilage destruction. A destabilization of the medial meniscus mouse model was established to investigate the effect of teriparatide in OA, particularly, on synovial inflammation and cartilage degradation.
Results:
In vitro experiments showed that TNF-α was the most potent inducer of cartilage matrix-degrading enzymes, and that teriparatide antagonized the TNF-α of effect. Consistently, articular cartilage samples from TNF-α transgenic mice contained more MMP-13 positive chondrocytes than those from wild type mice. In addition, more type II collagen was cleaved in human OA cartilage than in normal cartilage samples.
Conclusions:
Teriparatide can prevent synovitis and cartilage degradation by suppressing TNF-α mediated MMP-13 overexpression. Together with its chondroregenerative capability, teriparatide may be the first effective disease modifying osteoarthritis drug.
Insights
Teriparatide effectively treats osteoarthritis (OA) synovitis and cartilage degradation by suppressing tumor necrosis factor-alpha (TNF-α) induced matrix metalloproteinase-13 (MMP-13) overexpression, potentially offering disease modification.
Area of Science:
- Biomedical research
- Osteoarthritis pathogenesis
- Drug discovery
Background:
- Osteoarthritis (OA) is a degenerative joint disease characterized by low-grade inflammation.
- Inflamed synovium releases cytokines that drive cartilage destruction and pain.
- Teriparatide, an anti-osteoporotic drug, has shown potential in cartilage repair.
Purpose of the Study:
- To investigate the role of teriparatide in OA synovitis.
- To identify key cytokines involved in OA inflammation and cartilage destruction.
- To evaluate teriparatide's therapeutic potential in an OA mouse model.
Main Methods:
- Primary mouse articular chondrocytes were used for in vitro studies.
- A destabilization of the medial meniscus (DMM) mouse model was employed.
- Cytokine-induced cartilage degradation and teriparatide's effects were analyzed.
Main Results:
- Tumor necrosis factor-alpha (TNF-α) was identified as a potent inducer of cartilage matrix-degrading enzymes.
- Teriparatide antagonized TNF-α's pro-degradative effects in vitro.
- MMP-13 overexpression and type II collagen cleavage were reduced by teriparatide in OA models.
Conclusions:
- Teriparatide suppresses TNF-α-mediated MMP-13 overexpression, preventing synovitis and cartilage degradation.
- Teriparatide exhibits chondroregenerative properties.
- Teriparatide may represent a novel disease-modifying osteoarthritis drug.
